Appeals court affirmed that SM-102 does not infringe Alnylam’s mRNA patents. The decision supports Moderna’s use of SM-102 in its Spikevax COVID-19 vaccine. Live on Wednesday June 18: 3 Summer ...

At Alnylam, we believe that making history means advancing groundbreaking science while shaping a healthier, more equitable, and sustainable future for all," said Yvonne Greenstreet, M.D., Chief ...

An Alnylam spokesperson said the company was evaluating its options and may appeal. A BioNTech spokesperson said the filing "confirms Pfizer's and BioNTech's position that we do not infringe any ...

Twenty-two years in and Alnylam Pharmaceuticals is still not raking in any profit. But that’s a testament to the company’s R&D focus, because it takes more than one or two successful drugs to ...

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $57.5 million in its first quarter. The Cambridge, Massachusetts-based ...

Fintel reports that on March 24, 2025, JP Morgan upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from Neutral to Overweight. Analyst Price Forecast Suggests 11.73% Upside As of ...

Alnylam's Amvuttra and partner Sanofi's fitusiran have PDUFA dates with the FDA next month, and approvals should create new revenue sources for the company. Alnylam's 2025 guidance for the TTR ...

Analyst Price Forecast Suggests 13.99% Upside As of October 22, 2024, the average one-year price target for Alnylam Pharmaceuticals is $306.60/share. The forecasts range from a low of $179.78 to a ...

Alnylam concedes its inability to secure a judgment against Moderna’s products after the court’s claim construction. Moderna’s counterclaims and affirmative defenses were dismissed without ...